New Study Debunks Statin Side Effect Fears: Minimal Risks, Big Heart Benefits

**Oxford Population Health**, formally the Nuffield Department of Population Health (NDPH) at the University of Oxford, drives cutting-edge research to combat major diseases through large-scale population studies and global collaborations.[1][2] Established in July 2013 by merging eleven research units from Oxford's Medical Sciences Division, it honors Viscount Nuffield's legacy in medical sciences since the 1930s; in 2021, it adopted the bold "Oxford Population Health" brand to spotlight its focus on preventing avoidable suffering via population health science.[1][2] The department excels in **large-scale epidemiological studies** like the Million Women Study (1.3 million participants), probing disease causes, prevention, and treatments across developed and developing worlds.[1] It conducts the world's largest randomized controlled trials, health services research, and develops Patient-Reported Outcome Measures (PROMs) for chronic conditions such as knee pain and Parkinson's.[1] Key contributions include evidence on statins' efficacy, meat reduction benefits, and women's health, plus genomics insights for healthcare systems.[2] With over 500 researchers, NDPH integrates epidemiology, statistics, health economics, ethics, and big data at facilities like the Richard Doll Building and the 2017-opened Big Data Institute (BDI).[2] Currently led by Prof. Prabhat Jha since 2025 (succeeding founder Sir Rory Collins), NDPH trains scientists via its DPhil in Population Health, fostering multidisciplinary skills for real-world impact—from UK Biobank analysis to trial follow-ups.[2][4][5] Its global reach tackles complex challenges like premature death and disability, blending observational data with innovative trials.[1][3] For business and tech audiences, NDPH's BDI exemplifies big data's role in health innovation, powering ethical AI-driven insights and scalable interventions that could transform public health economics and personalized medicine.[2] (Word count

**The Lancet** is a prestigious weekly peer-reviewed general medical journal, renowned as one of the world's highest-impact academic publications and the oldest still in print.[1] Founded in 1823 by English surgeon Thomas Wakley in London, it was named after the lancet scalpel and launched with a radical mission to expose corruption, nepotism, and incompetence in the medical establishment.[1][2] Wakley, a reformer frustrated by London's healthcare scandals, aimed to democratize medical knowledge by reprinting exclusive hospital lectures for free—sparking controversy but rapidly growing subscriptions to over 8,000 within seven years.[1] By 1840, *The Lancet* dominated UK medical news, advocating for reforms that reshaped British healthcare, hospitals, and evidence-based practices.[1][2] Its bold stance evolved into global influence, publishing original research, seminars, reviews, editorials, case reports, and news features. Key achievements include pioneering medical advancements and policy shifts, cementing its status as a top-tier journal with immense citation impact.[1] Since 1991, Elsevier has owned it, with Richard Horton as editor-in-chief from 1995 onward; editorial offices span London, New York, and Beijing for worldwide reach.[1] Today, *The Lancet* thrives as a cornerstone of medical publishing, blending rigorous science with commentary on global health challenges like pandemics and inequities. For business and technology enthusiasts, its model highlights scalable academic media empires: Elsevier's ownership drives profitability through subscriptions and open-access hybrids, while digital innovations amplify tech-driven research dissemination. With influence rivaling tech giants in shaping biotech investments and AI-health intersections, *The Lancet* exemplifies how legacy institutions adapt to modern data revolutions—proving timeless authority in an era of rapid innovation.[1][2] (Word count: 298)